Services on Demand
Journal
Article
Indicators
Cited by SciELO
Related links
Similars in SciELO
Share
Revista argentina de dermatología
On-line version ISSN 1851-300X
Abstract
LUGO, SM; CAMACHO, ME; MONTOYA, YC and VIVAS, SC. Psoriasis during treatment with Natalizumab in multiple sclerosis patient. Rev. argent. dermatol. [online]. 2018, vol.99, n.2, pp.1-10. ISSN 1851-300X.
The prevalence of psoriasis among patients with multiple sclerosis ranges from 1.59 to 7.7%. They share genetic and pathogenic characteristics where the main role is fulfilled by T lymphocytes (Th1-Th17), its activation triggers the release of proinflammatory cytokines, favoring the development of inflammatory events characteristic of both entities. Natalizumab, used in the treatment of patients with multiple sclerosis can trigger psoriasis, blocking some of the adhesion molecules or inflammatory pathways, which can be compensate by other pathways, and produce paradoxical immune reactions.
Keywords : psoriasis; multiple sclerosis; natalizumab.